相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- OncoDaily Medical Journal, the official journal of the Immune Oncology Research Institute, has added 20 new editorial team members from 12 countries across two recent recruitment waves. - The new editors bring expertise spanning immuno-oncology, precision medicine, pediatric oncology, sarcoma, melanoma, and hereditary cancers, strengthening the journal's global reach. - Notable appointments include specialists from City of Hope, Fox Chase Cancer Center, Cleveland Clinic, and other leading cancer institutions worldwide. - The expansion aims to advance the journal's mission of bridging research, clinical practice, and education in oncology through high-quality, peer-reviewed content.
- A multicenter DESTINEX study published in JAMA Surgery validates Cizzle Bio's DEX-G2 blood test, achieving 95% sensitivity for detecting early-stage gastric cancer and 96.8% diagnostic accuracy. - The study analyzed 809 blood samples from 480 participants across leading medical centers in Japan and South Korea, demonstrating robust performance across different tumor stages and patient subgroups. - DEX-G2 offers a minimally invasive alternative to endoscopic screening for gastric cancer, the third leading cause of cancer-related deaths worldwide, with over 60% of cases diagnosed at advanced stages. - Cizzle Bio is preparing DEX-G2 for commercial deployment in CLIA-certified laboratories, holding worldwide exclusive licensing rights for the biomarker-based diagnostic tool.
• New research reveals 76% of renal cell carcinoma clinical trials are conducted exclusively in high-income countries, despite poverty being strongly linked to worse disease outcomes. • Study findings highlight significant racial disparities in trial participation, with Black patients comprising only 5% of participants despite representing 13% of the US population. • Experts emphasize that expanding clinical trials to low-income countries could improve treatment efficacy understanding across diverse populations and lead to more cost-effective therapeutic approaches.
- The SWOG 1500 phase II trial found no statistically significant overall survival benefit with cabozantinib compared to sunitinib in advanced papillary renal cell carcinoma. - Median overall survival was 21.5 months for cabozantinib versus 17.3 months for sunitinib, with a hazard ratio of 0.83 (95% CI: 0.51–1.36, P = .46). - Cabozantinib did show improved progression-free survival and objective response rate compared to sunitinib in the primary analysis. - The study underscores the need for novel therapeutic strategies to improve outcomes in patients with advanced papillary renal cell carcinoma.
